Compare Bristol-Myers Squibb Co (BMY) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Genuine Parts Company — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while Genuine Parts Company trades at $121.74 (market cap $16.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.9× Genuine Parts Company's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | GPC | |
|---|---|---|
Market Cap | $116.30B | $16.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $149.26 |
52-Week Low | $42.60 | $92.47 |
Enterprise Value | $152.24B | $23.03B |
Dividend Yield | 4.42% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
GPC trades at $123.52, down 1.67% over the past day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results expected on July 21, 2026. Revenue growth remains modest at $24.3B in 2025, though net income margins have compressed significantly to 0.24%. Analyst sentiment is mixed with a consensus price target of $133.00, representing a 7.7% upside from current levels.
GPC offers potential for moderate upside based on analyst targets and dividend stability, but faces headwinds from declining profitability margins and recent earnings misses. The stock's high P/E ratio of 280.73 suggests premium valuation despite weak earnings growth, while strong cash flow generation and Dividend King status provide some downside protection. Key risks include margin pressure and competitive threats in the automotive parts distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
